1. Home
  2. CNTX vs SRL Comparison

CNTX vs SRL Comparison

Compare CNTX & SRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CNTX
  • SRL
  • Stock Information
  • Founded
  • CNTX 2015
  • SRL 2017
  • Country
  • CNTX United States
  • SRL China
  • Employees
  • CNTX N/A
  • SRL N/A
  • Industry
  • CNTX Biotechnology: Pharmaceutical Preparations
  • SRL Professional Services
  • Sector
  • CNTX Health Care
  • SRL Consumer Discretionary
  • Exchange
  • CNTX Nasdaq
  • SRL Nasdaq
  • Market Cap
  • CNTX 75.6M
  • SRL 81.5M
  • IPO Year
  • CNTX 2021
  • SRL N/A
  • Fundamental
  • Price
  • CNTX $0.85
  • SRL $5.34
  • Analyst Decision
  • CNTX Strong Buy
  • SRL
  • Analyst Count
  • CNTX 5
  • SRL 0
  • Target Price
  • CNTX $5.25
  • SRL N/A
  • AVG Volume (30 Days)
  • CNTX 121.2K
  • SRL 2.4K
  • Earning Date
  • CNTX 11-05-2025
  • SRL 04-30-2025
  • Dividend Yield
  • CNTX N/A
  • SRL 19.81%
  • EPS Growth
  • CNTX N/A
  • SRL N/A
  • EPS
  • CNTX N/A
  • SRL N/A
  • Revenue
  • CNTX N/A
  • SRL $24,535,042.00
  • Revenue This Year
  • CNTX N/A
  • SRL N/A
  • Revenue Next Year
  • CNTX N/A
  • SRL N/A
  • P/E Ratio
  • CNTX N/A
  • SRL N/A
  • Revenue Growth
  • CNTX N/A
  • SRL N/A
  • 52 Week Low
  • CNTX $0.49
  • SRL $5.13
  • 52 Week High
  • CNTX $2.59
  • SRL $9.99
  • Technical
  • Relative Strength Index (RSI)
  • CNTX 55.84
  • SRL 47.58
  • Support Level
  • CNTX $0.81
  • SRL $5.22
  • Resistance Level
  • CNTX $0.87
  • SRL $5.50
  • Average True Range (ATR)
  • CNTX 0.05
  • SRL 0.11
  • MACD
  • CNTX -0.01
  • SRL 0.02
  • Stochastic Oscillator
  • CNTX 39.79
  • SRL 55.97

About CNTX Context Therapeutics Inc.

Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

Share on Social Networks: